ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SENS Senseonics Holdings Inc

0.492151
-0.00355 (-0.72%)
Last Updated: 18:04:06
Delayed by 15 minutes
Share Name Share Symbol Market Type
Senseonics Holdings Inc AMEX:SENS AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.00355 -0.72% 0.492151 0.495 0.4778 0.4778 1,080,535 18:04:06

Senseonics Holdings, Inc. Schedules First Quarter 2019 Earnings Release & Conference Call for May 9, 2019 at 4:30 p.m. Easter...

25/04/2019 9:05pm

Business Wire


Senseonics (AMEX:SENS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Senseonics Charts.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its first quarter 2019 financial results after market close on Thursday, May 9, 2019.

Management will hold a conference call to review the company’s first quarter 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 888-378-4398 (US/Canada) or 786-789-4775 (International), passcode 756769, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

INVESTOR CONTACTLynn Lewis or Philip TaylorInvestor Relations415-937-5406investors@senseonics.com

1 Year Senseonics Chart

1 Year Senseonics Chart

1 Month Senseonics Chart

1 Month Senseonics Chart